Default company panoramic image
3522e893 916f 428d 9666 e7d700b0b8f1

Sentinel Therapeutics, Inc.

Sentinel is a clinical stage company developing a patented immunotherapy as a non-surgical alternative to treat skin cancer (BCC, melanoma).

  • Stage Product In Development
  • Industry Biotechnology
  • Location Vancouver, WA, USA
  • Currency USD
  • Founded September 2012
  • Website

Company Summary

Sentinel is developing ST1042 to treat skin cancers. This product has completed Ph 1-2a trials in the US and Europe and is in a 2a trial now. ST1042 has been shown to be safe and effective in treating forms of skin cancer. The next trial will be in BCC, the most common form of skin cancer. ST1042 will provide a non-surgical approach to treat BCC facial lesions where excision is not desirable. The market is over 2 MM procedures.


  • Default avatar
    David Pritchard
    President and CEO

    Former biotech CEO, VP BD. Broad international experience in licensing, M&A and financing. Working on current skin cancer project since 2009.